On October 31st, Amgen, the American pharmaceutical company, reported an adjusted eps of $5.58 for the third quarter, with analysts expecting $5.10. The third-quarter revenue was $8.5 billion, with analysts expecting $8.52 billion; adjusted eps for the full year are expected to be $19.20-20, previously forecasted at $19.10-20.10; full-year revenue is projected to be $33 billion-33.8 billion, previously estimated at $32.8 billion-33.8 billion.
安进第三财季调整后每股收益超过预期
Amgen's third quarter adjusted earnings per share exceeded expectations.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated